Biopharmaceutical - Clinical-Stage Infectious Disease Drug Development
Strategic Profile
AN2 has a pipeline of boron-based compounds in development for Chagas disease, melioidosis, and NTM lung disease caused by M. abscessus, along with programs focused on targets in oncology and infectious diseases. The company recently announced a collaboration agreement with GSK to develop new therapies for tuberculosis (TB), with the Gates Foundation providing funding to support AN2's work within the collaboration. This positions AN2 as a specialized player leveraging proprietary boron chemistry across multiple high-impact infectious disease areas.
Cyborg Score Rationale
Epetraborole demonstrated potential proof-of-concept in Phase 2, achieving nominal statistical significance on patient-reported outcome measures in treatment-refractory MAC lung disease, with Phase 3 topline results expected in Q2 2025. Strategic partnerships with GSK and Gates Foundation funding validate the platform. Clinical-stage focus carries execution risk but targets critical unmet needs.
Top Insights
The company recently dosed the first Phase 1 cohort in Chagas disease and announced a collaboration with Drugs for Neglected Diseases initiative to advance Phase 2 preparations.
GSK collaboration for tuberculosis development represents major pharma validation of the boron chemistry platform.
A 200-patient observational study in acute melioidosis highlighted the acute lethality of this bacterial infection and recognized biothreat.
Multi-indication pipeline spanning Chagas, melioidosis, NTM, and oncology reduces single-program development risk.
Named Competitors
Infectious Disease Programs — Clinical-stage biopharmaceutical company
Therapeutic Programs — Precision medicine oncology focus
Cell Therapy Programs — Natural killer cell therapy development
Recent Developments
(Q3 2025) GSK tuberculosis collaboration with Gates Foundation funding commitment
(Q2 2025) Phase 3 epetraborole results expected and melioidosis observational study completion
(Q1 2025) Phase 1 Chagas disease dosing initiated and DNDi partnership announced
Open the full interactive AN2 Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.